Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Instagram Outage Disrupts Thousands of U.S. Users 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
ROCKVILLE, Md., June 07, 2017 -- American Gene Technologies International Inc. (AGT), a genetic medicine company with a broad, robust lentiviral delivery platform, announced today that its CEO, Jeff Galvin, is presenting at the upcoming BIO International Convention. The Convention is being held on June 19-22, at the San Diego Convention Center in California. AGT’s presentation is scheduled for Monday, June 19, at 1:30 p.m. PDT. Mr. Galvin will discuss the company’s three lead programs in infectious disease, phenylketonuria and oncology and its innovative lentiviral platform. Interested Investors and collaborators are invited to attend and schedule one-on-one meetings.
About American Gene Technologies
AGT has a proprietary lentiviral platform capable of broad applications including: large and orphan indications, immuno-oncology, and monogenic disorders. AGT will enter the clinic in 2017 with a Phase 1 clinical trial to evaluate AGT103 as a functional cure for HIV. Pre-IND applications for phenylketonuria (“PKU”) and hepatocellular carcinoma (“HCC”) will follow. These therapies demonstrate the breadth of AGT’s unique lentiviral platform, including such innovations as a Transient Vector™ for temporary expression and an ImmunoTox™ vector for stimulating anti-tumor immunity in immuno-oncology applications.
AGT has developed extensive IP surrounding its lentiviral platform innovations. These innovations accelerate the development of a wide variety of drug candidates, provide significant opportunities for out-licensing, and offer exciting clinical opportunities. AGT is currently closing a funding round to support the initial human trial of the HIV functional cure and the preclinical development of PKU and HCC. More information can be found at www.americangene.com.
About the Event.
BIO International Convention is the Biotechnology Innovation Organization’s lead event for growing the global biotech industry through education, partnering and networking among international industry leaders from biotech, academia, pharma and investors.
AGT, contact: Shannah Koss, Chief Operating Officer Phone: (301) 337-2275 Email: [email protected] Media Contact: Cari P. Randall 646-536-7002 [email protected]
